Abstract
Psoriasis is a chronic, immune-mediated, inflammatory, and debilitating skin disease with significant impact on patients' quality of life. Its pathogenesis is complex and not yet fully understood. However, the IL-23/IL-17 axis is currently considered the main pathogenic pathway in psoriasis. Guselkumab is a fully human immunoglobulin G1 λ (IgG1λ) monoclonal antibody (mAb) that binds to the p19 subunit of IL-23. It is the first of its class, already approved by the US Food and Drug Administration (FDA), as well as the European Medicines Agency (EMA) for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for either systemic therapy or phototherapy. Several clinical trials have demonstrated potential benefits of guselkumab over other already approved immunomodulators in terms of safety and efficacy. The results of the head-to-head trial ECLIPSE were recently released and are addressed in this review. They contribute to the increasing confidence in guselkumab, demonstrating great potential for long-term treatment of psoriasis. However, further long-term data and additional comparative studies will be essential for positioning guselkumab in the therapeutic armamentarium for psoriasis.
Citations
Apr 22, 2020·Immunotherapy·Cristina López-Sánchez, Lluís Puig
Apr 20, 2020·Dermatologic Therapy·Cristina MughedduFranco Rongioletti
Jun 12, 2020·Carcinogenesis·Ye TaoYehai Liu
Jun 20, 2020·Dermatologic Therapy·Uwe WollinaWolfgang G Philipp-Dormston
Jul 2, 2020·American Journal of Clinical Dermatology·Radomir ReszkeJacek C Szepietowski
Sep 29, 2020·Frontiers in Immunology·Mohamed A AlfalehAnwar M Hashem
Sep 5, 2020·Clinical, Cosmetic and Investigational Dermatology·Egídio FreitasTiago Torres
Oct 27, 2020·Advanced Healthcare Materials·Ana Cláudia LimaNuno M Neves
Oct 1, 2020·The British Journal of Dermatology·R ReddyD Rosmarin
Dec 29, 2020·Frontiers in Neurology·Austin NegronThomas G Forsthuber
Oct 15, 2020·International Journal of Molecular Sciences·Michio Tokuyama, Tomotaka Mabuchi
Apr 4, 2021·Paediatric Drugs·Miguel NogueiraTiago Torres
May 1, 2021·International Journal of Clinical Practice·Teodora-Larisa TimisRemus-Ioan Orasan
Aug 11, 2021·Pharmaceutics·Jen-Chih TsengTsung-Hsien Chuang
Aug 29, 2021·The Journal of Dermatology·Yukari OkuboTadashi Terui